NDC 63323-0472-17
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 63323-0472-17
- Product root
- 63323-0472
- Identity scope
- Package
- Primary current NDC product row
- Not present
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 63323-472 | 63323-472-17 | D | Discontinued by firm | 2026-07-31 |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SENSORCAINE | BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE | Fresenius Kabi USA, LLC | bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb | 2023-04-30 | Boxed warning, Warnings, Adverse reactions | 63323047217 |